Selected Start-Ups (03/01)
In Vivo summarizes the technology of several recently founded companies: Germany's Curacyte AG was formed to commercialize platforms in oncology, immunology and hematological disorders; Eliance Biotechnology Inc. has licensed a vaccine discovery platform that identifies the optimal antigens for vaccine production; Immerge Biotherapeutics will focus on the development of swine-based cells, tissues and organs for transplantation into humans; MedLynx Corp. aims to reduce hospital operating costs and reduce medical errors with its wireless, handheld medical information management system; Perlegen Sciences Inc. will read genomes from 50 individuals to discover and analyze patterns of genetic variation; Protiva Biotherapeutic Inc's gene delivery technology protects plasmid DNA from degradation as the particles are delivered through the bloodstream to their destination
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.